This cellular damage was attenuated by rebamipide in a dose dependent manner. Furthermore, spectrophotometrical measurement showed that rebamipide (1 mM) inhibits urease activity by 21 .7%.
As monochloramine (an oxidant yielded by reaction of neutrophil derived chlorinated oxidant and ammonia) is proposed as an important toxic molecule in this model, the current findings suggest that the preventive effect of rebamipide on H pylon elicited neutrophil induced gastric mucosal injury may result from its inhibitory actions on the neutrophilic oxidative burst as well as H pyloni derived urease activity. (Gut 1994; 35: 1375 -1378 Helicobacter pylori has been shown to be an important pathogen of gastric disorder including gastritis and gastric ulcer. The pathogenic mechanisms, however, by which H pyloni causes the gastric mucosal damage still remain obscure. Antibiotics have been, therefore, only recently been used for Hpylori positive patients for the purpose of bacterial eradication. One of the potential toxic factors involving gastric mucosal cell injury is reactive oxidants, which are released from activated neutrophils. Several studies have already shown that H pyloni itself exhibits chemotactic activity for neutrophils.1-5 We have also reported that H pylori elicited neutrophils produce toxic oxidants, which subsequently injure cultured gastric mucosal cells, and that ammonia, which is derived from urea by H pyloni associated urease enhances the mucosal cytotoxicity, which may be regulated by monochloramine.6 7 Considering these mechanisms, the agents that can inhibit either neutrophil activation or ammonia production are proposed to be effective for Hpyloni induced gastric mucosal injury. Rebamipide had been reported to promote mucus synthesis,8 mucosal prostaglandin content, and rapid ulcer healing.9 Moreover, it has recently been reported to inhibit the production of oxygen derived free radicals from stimulated neutrophils.10 In this report, we have evaluated whether rebamipide may influence active oxidant production elicited by H pyloni activated neutrophils and urease activity, and whether it attenuates gastric mucosal cell damage associated with H pylor activated neutrophils in vitro.
Methods

CHEMICALS
The fluorochrome dye 2',7'-bis (2- 
Discussion
Eradication treatment using antibiotics has been generally approved for the treatment of patients with H pyloni positive gastritis and gastric ulcer. Few therapeutic strategies, however, which can abolish the cytotoxic action of H pyloni have been described. Among H pyloni associated cytotoxic factors, chemotaxin, which is detectable in H pylori and its culture filtrate is one of the potential determinants of virulence because a significant neutrophil infiltration is characterised in H pylori positive gastric mucosa. l 12 Yoshida et al have reported that this active factor elicits the upregulation of leucocyte adhesion molecules causing neutrophil adherence to venular endothelium in rat mesentery and to monolayers of human umbilical vein endothelial cells.'3 Kurose et al have also seen that the mesenteric microvascular permeability is dramatically increased by H pylori extract, which is neutrophil mediated.'4 We have recently reported that H pyloni elicits chlorinated toxic oxidant production from neutrophils and that these substances play a critical part in H pylori associated gastric mucosal damage.6 7 Rebamipide is a quinolinon derivative and its molecular weight is 370 79. This compound has been reported to possess antiulcer properties against ethanol or acid induced gastric mucosal damage. These effects have been interpreted by its pharmacological action on prostaglandin synthesis in gastric epithelium.9 The local concentration of rebamipide has not been reported in the human stomach while its mucosal concentration is more than 0-2 mM after the oral intake of 10 mg/kg rebamipide in rats. ' that we used. '6 17 It is also known that FMLP (f-methionyl-leucyl-phenylalanine) stimulated neutrophil dependent superoxide production was inhibited by rebamipide.'8 It is, therefore, concluded that rebamipide may suppress active oxidant production through modulating the neutrophil activation process, independently of its radical scavenging properties. Accordingly, the attenuation of rebamipide on toxic oxidant release may be important in preventing gastric mucosal injury associated by H pylori elicited neutrophils. This toxic mechanism is supported by our experimental evidence that gastric mucosal cell damage associated with H pylori and neutrophils is significantly inhibited by rebamipide. This study shows that rebamipide significantly inhibits urease activity as well, which implies the possibility that the ammonia concentration can be reduced in gastric mucosa infected by Hpyloni. Although it is not certain how much H pylori associated urease can be inhibited by rebamipide at the concentration found in the human stomach, ammonia has been proposed to be an important pathogen to Hpylori associated gastric mucosal injury. The ammonia concentration of gastric juice is reported as 3-4 mM, which is not cytotoxic. '9 20 This concentration of ammonia, however, has been proposed to be pathogenic in the presence of activated neutrophils because neutrophil derived hypochlorous acid can react with ammonia to produce monochloramine, which is a highly toxic molecule. We have emphasised the unique role of monochloramine in Hpylori induced gastric mucosal damage.6 Morishita et al have also shown the clinical efficacy of taurine (monochloramine scavenger) for patients with H pylori positive gastritis.2' Although monochloramine concentration was not measured in this in vitro study and the attenuating magnitude of rebamipide on urease activity is comparatively slight (22% at 1 mM), the synchronous inhibition of rebamipide in neutrophilic oxidative bursts and H pylon derived urease activity may be advantageous for preventing H pylori induced gastric mucosal damage, which is mediated by monochloramine.
The in vitro bacterial growth test shows that bacterial growth of Hpylori is not influenced by rebamipide at concentrations less than 1 mM. This finding suggests that oral intake of rebamipide in itself cannot clinically eradicate H pyloni from gastric mucosa.
In conclusion, the results of this in vitro study suggest that rebamipide may be one of the valuable antiulcer compounds that also exhibit an additional efficacy for H pylorn induced mucosal damage associated with the ammonia monochloramine system. We thank Dr K Yamasaki (Otsuka Pharm) for providing the gastric epithelial cells. This work was supported by a grant-inaid for scientific research from the Ministry of Education, Science and Culture of Japan and by a grant from Keio University, School of Medicine.
